PRISM BioLab Co. LTD (JP:206A)
:206A
Want to see JP:206A full AI Analyst Report?
206A Stock Chart & Stats
¥160.00
-¥4.00(-1.25%)
At close: 4:00 PM EST
¥160.00
-¥4.00(-1.25%)
Day’s Range― - ―
52-Week Range¥132.00 - ¥282.00
Previous CloseN/A
Volume305.30K
Average Volume (3M)2.26M
Market Cap
¥6.32B
Enterprise Value¥3.22B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.94
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding36,964,000
10 Day Avg. Volume1,556,930
30 Day Avg. Volume2,256,993
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)2.27
Price to Sales (P/S)9.06
P/FCF Ratio-4.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Recent Revenue GrowthThe company reported very strong top-line expansion (over 74% revenue growth), demonstrating product or pipeline traction and market demand. Durable revenue momentum gives management time to scale scientific programs, attract partners, and justify continued R&D investment if growth persists.
Debt-free, Conservatively Financed Balance SheetHaving no reported debt materially lowers refinancing and interest-rate risk, preserving financial flexibility to fund R&D or pursue partnerships. This structural strength supports longevity during extended clinical or discovery timelines versus peers with leverage, improving resilience to funding cycles.
Proprietary Discovery Technology And Focused ExpertiseA focused drug-discovery approach targeting protein–protein interactions with proprietary technology creates a high technical barrier and differentiated pipeline potential. If validated clinically, this capability can sustain competitive advantage, enable selective partnerships, and drive durable value beyond short-term cycles.
Bears Say
Persistent Negative ProfitabilityDespite revenue growth, the company reports sustained negative EBIT and net income across multiple years. Ongoing operating losses reduce internal funding capacity, weaken margins, and require external capital to continue operations, making long-term execution contingent on improving unit economics or consistent financing.
Deteriorating Operating Cash Flow And Accelerating Cash BurnOperating cash flow volatility and persistent negative free cash flow signal accelerating cash burn, increasing funding and execution risk. This structural cash shortfall can force dilutive financing, delay programs, or constrain strategic options until cash generation stabilizes or new capital is secured.
Negative Returns And Equity VolatilityStrongly negative ROE and swings in equity reflect poor shareholder value creation and potential reliance on external financing. Equity volatility can hinder the company's ability to raise capital on favorable terms, increasing the cost of funding and pressuring strategic choices over the medium term.
PRISM BioLab Co. LTD News
206A FAQ
What was PRISM BioLab Co. LTD’s price range in the past 12 months?
PRISM BioLab Co. LTD lowest stock price was ¥132.00 and its highest was ¥282.00 in the past 12 months.
What is PRISM BioLab Co. LTD’s market cap?
PRISM BioLab Co. LTD’s market cap is ¥6.32B.
When is PRISM BioLab Co. LTD’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were PRISM BioLab Co. LTD’s earnings last quarter?
Currently, no data Available
Is PRISM BioLab Co. LTD overvalued?
According to Wall Street analysts PRISM BioLab Co. LTD’s price is currently Overvalued.
Does PRISM BioLab Co. LTD pay dividends?
PRISM BioLab Co. LTD does not currently pay dividends.
What is PRISM BioLab Co. LTD’s EPS estimate?
PRISM BioLab Co. LTD’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PRISM BioLab Co. LTD have?
PRISM BioLab Co. LTD has 36,964,000 shares outstanding.
What happened to PRISM BioLab Co. LTD’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PRISM BioLab Co. LTD?
Currently, no hedge funds are holding shares in JP:206A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PRISM BioLab Co. LTD
PRISM BioLab Co., LTD (206A) is a biotechnology company specializing in the discovery and development of small molecule drugs. The company focuses on innovative structural biology techniques to develop novel therapeutic agents targeting a range of diseases. Its core products include proprietary compounds aimed at addressing unmet medical needs in areas such as oncology and inflammatory diseases.
Technical Analysis
StemRIM Inc.
―
CellSource Co., Ltd.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―